<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85532">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01724450</url>
  </required_header>
  <id_info>
    <org_study_id>Cardiotox Incor</org_study_id>
    <nct_id>NCT01724450</nct_id>
  </id_info>
  <brief_title>Effect of Beta-Blockers in Preventing Chemotherapy - Induced Cardiotoxicity</brief_title>
  <official_title>Randomized Double Blind Study on the Effect of Beta-Blockers in Preventing Chemotherapy - Induced Cardiotoxicity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital A.C. Camargo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto do Cancer do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <authority>Brazil: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if carvedilol can prevent the cardiotoxicity after
      chemotherapy in breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dilated cardiomyopathy secondary to chemotherapy accounts for approximately 1% of all
      dilated cardiomyopathies.

      Initial studies showed beneficial effect of the use of carvedilol for the prevention of
      chemotherapy-induced cardiomyopathy. This study has the objective to evaluate the
      effectiveness of carvedilol for the prevention of chemotherapy-induced cardiomyopathy. Will
      be selected 200 patients referred for chemotherapy that includes  anthracyclines for breast
      cancer.These patients will be randomized to carvedilol or placebo and will have periodic
      assessment of cardiac function with echocardiography and biomarkers until complete
      chemotherapy and 24 months later.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Prevention of systolic dysfunction in patients undergoing chemotherapy with anthracycline. Systolic dysfunction is characterized by a 10% drop in ejection fraction of left ventricle.</measure>
    <time_frame>96 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevention of myocardial injury measured by the levels of biomarkers (ultrasensitive troponin, BNP and miRNA-208) Effect of carvedilol in the prevention of diastolic dysfunction.</measure>
    <time_frame>96 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Heart Failure</condition>
  <condition>Cardiotoxicity</condition>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>50mg/day for 24 weeks. The dose of carvedilol will be up titrate before the dose of 50mg/day</description>
    <arm_group_label>Carvedilol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo similar to the carvedilol up titration but wit no active drug.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients diagnosed with breast cancer, with an indication of chemotherapy that includes
        anthracycline.

        Exclusion Criteria:

        Failure analysis of ventricular function; History of chemotherapy or radiotherapy;
        Previous symptoms of heart failure; Presence of cardiomyopathy; Presence of Coronary
        Artery Disease; Aortic valve disease or moderate to severe mitral regurgitation;
        Contraindication to the use of β-blocker; Use of inhibitors of angiotensin converting
        enzyme, angiotensin receptor blockers or β-blockers.

        Patients with HER 2 expression
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edimar Alcides Bocchi, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Institute of University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edimar Alcides Bocchi, PHD</last_name>
    <phone>+551126615419</phone>
    <email>edimar.bocchi@incor.usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silvia Moreira Ayub-Ferreira, PHD</last_name>
    <phone>+551126615419</phone>
    <email>silvia.ayub@incor.usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart Institute University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edimar Alcides Bocchi, PHD</last_name>
      <phone>+551126615419</phone>
      <email>edimar.bocchi@incor.usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Silvia Moreira Ayub-Ferreira, PHD</last_name>
      <phone>+551126615419</phone>
      <email>silvia.ayub@incor.usp.br</email>
    </contact_backup>
    <investigator>
      <last_name>Monica Samuel Avila, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Solange Moraes Sanches, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 6, 2012</lastchanged_date>
  <firstreceived_date>June 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Edimar Alcides Bocchi</investigator_full_name>
    <investigator_title>phd</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Cardiotoxicity</keyword>
  <keyword>Biomarkers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
